Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CET

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
12/08 ASTELLAS PHARMA : Research & Development Meeting Highlights
12/02 ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
12/01 ASTELLAS PHARMA : Immunomic Therapeutics Announces Expansion of IP Portfolio
11/30 ASTELLAS PHARMA : Initiatives to Pursue Operational Excellence
11/23 CASE STUDY : Application of SORS (RapID) to In-Container Testing of Raw Material..
11/21 ASTELLAS PHARMA : Antihypertensive Drug 'Micatrio Combination Tablets'
11/18 ASTELLAS PHARMA : Antihypertensive Drug "Micatrio® Combination Tablets"
11/17 ASTELLAS PHARMA : GUINNESS WORLD RECORDS Title Achieved for Organ Donor Registra..
11/09 ASTELLAS PHARMA : GUINNESS WORLD RECORDSTM Title Achieved for Organ Donor Regist..
11/03 ASTELLAS PHARMA : FDA Approves Supplemental New Drug Application for XTANDI enza..
More news
Sector news : Pharmaceuticals - NEC
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/30 Astellas on the prowl for acquisitions to stoke growth
11/08 Ionis Bids For Broad Nusinersen Label
10/31 Astellas Pharma, Inc. 2017 Q2 - Results - Earnings Call Slides
10/28 Astellas Pharma reports 1H results
10/12 Bispecific Interest Reaches A Crescendo
Advertisement
Financials ( JPY)
Sales 2017 1 320 118 M
EBIT 2017 275 000 M
Net income 2017 202 215 M
Finance 2017 478 969 M
Yield 2017 2,26%
P/E ratio 2017 15,95
P/E ratio 2018 15,11
EV / Sales 2017 2,14x
EV / Sales 2018 1,96x
Capitalization 3 300 734 M
More Financials
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 1 952  JPY
Spread / Average Target 27%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Masafumi Nogimori Chairman
Yasumasa Masuda Senior Executive Officer & Head-Finance
Mitsunori Matsuda Senior Executive Officer & GM-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-10.80%28 621
JOHNSON & JOHNSON9.29%305 407
ROCHE HOLDING LTD.-17.58%193 824
PFIZER INC.-4.15%192 367
NOVARTIS AG-18.49%182 959
MERCK & CO., INC.15.92%168 820
More Results